Strategies to Enhance CAR ‐T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization
American Journal of Hematology · 2026-02 · 101 (2) · 318-336
DOI: 10.1002/ajh.70131 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 08.11.2025. Verfasst von Mengqi Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 154 Literaturangaben. Gefördert von: Science and Technology Program for Medicine and Health in Zhejiang Province (General Program), National Natural Science Foundation of China, Zhejiang Province Vanguard Geese Leading Plan Project.
Abstract (Originalsprache)
Chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable clinical efficacy in treating hematological malignancies. Nevertheless, the limited persistence of CAR‐T cells in vivo remains a major therapeutic hurdle, leading to disease relapse. This review examines current strategies to enhance CAR‐T cell durability, focusing on recent advances in CAR structural design, gene editing techniques, ex vivo culture optimization, clinical management approaches, and in vivo preparation. By integrating insights from preclinical studies and clinical trials, we provide a comprehensive analysis of methods to prolong CAR‐T cell persistence from a technical perspective and discuss future directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.
- Institute of Hematology, Zhejiang University, Hangzhou, China.
- Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China.
ORCID-Profile: Yongxian Hu
Förderung
- Science and Technology Program for Medicine and Health in Zhejiang Province (General Program)
- National Natural Science Foundation of China
- Zhejiang Province Vanguard Geese Leading Plan Project
Zitieren
APA
Yu, M., Yang, T., Ding, S., & Hu, Y. (2026). Strategies to Enhance CAR ‐T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization. American Journal of Hematology, 101(2), 318-336. https://doi.org/10.1002/ajh.70131
Vancouver
Yu M, Yang T, Ding S, Hu Y. Strategies to Enhance CAR ‐T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization. American Journal of Hematology. 2026;101(2):318-336. doi:10.1002/ajh.70131
BibTeX
@article{Yu2026,
author = {Yu, Mengqi and Yang, Tingting and Ding, Shuyi and Hu, Yongxian},
title = {Strategies to Enhance CAR ‐T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical Optimization},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {2},
pages = {318--336},
doi = {10.1002/ajh.70131}
}
EUVIMED